Larimar Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-52.0M | $-52.6M | $660.0K | $10.1M |
| FY2017 | $-43.8M | $-43.8M | $55.0K | $8.3M |
| FY2018 | $-51.5M | $-51.6M | $108.0K | $9.6M |
| FY2019 | $-22.7M | $-22.8M | $83.0K | $129.0K |
| FY2020 | $-42.2M | $-42.3M | $62.0K | $2.2M |
| FY2021 | $-42.1M | $-42.4M | $333.0K | $5.5M |
| FY2022 | $-27.6M | $-27.7M | $100.0K | $6.6M |
| FY2023 | $-33.5M | $-33.6M | $164.0K | $7.6M |
| FY2024 | $-70.8M | $-71.3M | $515.0K | $8.8M |
| FY2025 | $-113.2M | $-113.3M | $91.0K | $7.0M |